172 related articles for article (PubMed ID: 2449084)
21. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
Lucas JG; Tuttle SE
J Surg Oncol; 1987 May; 35(1):30-4. PubMed ID: 2437407
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
23. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
24. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
25. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
26. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
Galloway ML; Murray D; Moffat DF
Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
[No Abstract] [Full Text] [Related]
27. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
Cibas ES; Corson JM; Pinkus GS
Hum Pathol; 1987 Jan; 18(1):67-74. PubMed ID: 2434407
[TBL] [Abstract][Full Text] [Related]
28. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
[TBL] [Abstract][Full Text] [Related]
29. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma.
Gibbs AR; Harach R; Wagner JC; Jasani B
Thorax; 1985 Feb; 40(2):91-5. PubMed ID: 2579450
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
Otis CN; Carter D; Cole S; Battifora H
Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
[TBL] [Abstract][Full Text] [Related]
31. The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.
Joglekar VM; Oliver D; Harris M
Br J Ind Med; 1991 Jan; 48(1):34-7. PubMed ID: 1704251
[TBL] [Abstract][Full Text] [Related]
32. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
33. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.
Hammar SP; Bockus DE; Remington FL; Rohrbach KA
Ultrastruct Pathol; 1996; 20(4):293-325. PubMed ID: 8837337
[TBL] [Abstract][Full Text] [Related]
34. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
35. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
36. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
39. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
Attanoos RL; Webb R; Gibbs AR
Histopathology; 1997 Mar; 30(3):260-3. PubMed ID: 9088956
[TBL] [Abstract][Full Text] [Related]
40. Differences in lectin binding patterns of normal endometrium and endometrial adenocarcinoma, with special reference to staining with Ulex europeus agglutinin 1 and peanut agglutinin.
Aoki D; Nozawa S; Iizuka R; Kawakami H; Hirano H
Gynecol Oncol; 1990 Jun; 37(3):338-45. PubMed ID: 1693583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]